McDonald's Revenues Expected To Increase, Plus Merck And More On CNBC's 'Final Trades'
Portfolio Pulse from Avi Kapoor
On CNBC's 'Halftime Report Final Trades,' Joseph Terranova recommended Merck & Co., despite the FDA's CRL on gefapixant for RCC and UCC. Stephanie Link expects McDonald's revenues to rise, citing legal action by GAR against BDS Malaysia and a Buy rating from HSBC with a $317 target. Bryn Talkington highlighted Pacer US Cash Cows 100 ETF's high free cash flow yield as a strong trade for 2024. Merck's stock rose 1.4%, McDonald's fell 0.9%, and COWZ dropped 0.5% on Wednesday.
January 04, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merck received a CRL from the FDA for gefapixant, but was still recommended by Joseph Terranova on CNBC. The stock rose 1.4%.
The FDA's CRL is a negative development for Merck, but the recommendation by a CNBC analyst and the subsequent stock rise suggest a mixed short-term impact.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Pacer US Cash Cows 100 ETF has a high free cash flow yield, recommended as a good trade for 2024 by Bryn Talkington. The ETF lost 0.5%.
The high free cash flow yield and the endorsement for 2024 suggest a positive outlook for COWZ, despite the slight decline in its recent price.
CONFIDENCE 70
IMPORTANCE 65
RELEVANCE 60
POSITIVE IMPACT
McDonald's revenues are expected to increase, supported by a Buy rating from HSBC with a $317 price target, despite a legal action by GAR against BDS Malaysia. The stock fell 0.9%.
Positive revenue expectations and a strong analyst rating indicate a bullish outlook for McDonald's, which may outweigh the short-term negative price movement and legal issues.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 80